UGF3 reinspection delay
FDA reinspection for UGF3 facility is pending; timeline is uncertain (up to 8 months from September 2025), delaying injectable product launches.
high · analyst_question
Aurobindo Pharma Limited — Q2 FY26
Aurobindo Pharma reported Q2 FY26 consolidated revenue of INR 8,286 crore (+6% YoY) and EBITDA of INR 1,678 crore (20.3% margin, +7% YoY).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Pen-G MIP policy uncertainty
Minimum import price (MIP) representation to government is pending; if delayed or denied, Pen-G ramp-up and profitability may be impacted.
medium · management_commentaryBiosimilar competitive intensity
New FDA draft guidance may lower entry barriers, increasing competition; Aurobindo may be third or later entrant in key products like denosumab.
medium · analyst_questionHigh CapEx intensity
H1 CapEx at INR 1,500 crore; ongoing investments in biosimilars, biologics CMO, and Pen-G may pressure cash flows despite unutilized capacities.
medium · analyst_question